B O O K - American College of Rheumatology

ACR/ARHP Poster Session C
262
1834. Subcutaneous (SC) Abatacept Is Well-Tolerated, Demonstrates
Clinical Efficacy and Is Associated with Low Immunogenicity
Following Withdrawal and Re-Introduction: Phase III
Evaluation in Rheumatoid Arthritis (RA) Patients Responding
to Abatacept. Jeffrey L. Kaine 6 , Geoffrey S. Gladstein 5 , Ingrid
Strusberg 4 , Manuel Robles 2 , Ramesh Pappu 1 , Ingrid Delaet 1 ,
Miranda Pans 1 and Charles L. Ludivico 3 , 1 Bristol-Myers Squibb
Co, Princeton, NJ, 2 Centro Médico Toluca, Metepec, Mexico,
3
East Penn Rheumatology Associates, East Stroudsburg,
Philadelphia, PA, 4 Instituto Reumatológico, Strusberg, Cordoba,
Argentina, 5 New England Research Associates, Trumbull, CT,
6
Sarasota Arthritis Center, Sarasota, FL.
1835. Subcutaneous Golimumab Sustains Effects of Intravenous
Golimumab in Patients with Active Rheumatoid Arthritis:
Results of the GO-LIVE Long Term Extension. Joel M. Kremer 4 ,
Peter Taylor 3 , Alan Mendelsohn 2 , Daniel G. Baker 1 , Lilianne
Kim 2 and Christopher T. Ritchlin 5 , 1 Centocor Research and
Development, Inc., Malvern, PA, 2 Centocor Research and
Development, Inc., 3 Imperial College of London, 4 The Center
for Rheumatology, Albany, NY, 5 University of Rochester Medical
Center, Rochester, NY.
1836. Sustained and Clinically Meaningful Improvements in Both
Day- and Night-Time Aspects of HRQoL Are Observed with
Abatacept Treatment in Patients with Rheumatoid Arthritis
(RA) and Previous Inadequate Response to MTX: 5-Year Data
from the AIM Trial. Joel Kremer 2 , Anthony S. Russell 3 , Rene
Westhovens 5 , Julie Teng 1 , Lisa Rosenblatt 1 and Paul Emery 4 ,
1
Bristol-Myers Squibb, Princeton, NJ, 2 Center for Rheumatology,
Albany Medical College, Albany, NY, 3 University of Alberta
Hospital, Edmonton, AB, Canada, 4 University of Leeds, Leeds,
United Kingdom, 5 UZ Gasthuisberg, Leuven, Belgium.
1837. Sustained and Clinically Meaningful Improvements in Physical
Function and Fatigue and Reductions in Activity Limitation
Are Observed in MTX-Naïve Patients with Early Rheumatoid
Arthritis (RA) Treated with Abatacept over 2 Years of the
AGREE Trial. Rene Westhovens 5 , Jurgen Wollenhaupt 4 , Boulos
Haraoui 2 , Jean-Claude Becker 1 , Allison Covucci 1 , Lisa Rosenblatt 1
and Joan Bathon 3 , 1 Bristol-Myers Squibb, NJ, 2 Institut de
Rumatologie de Montreal, Montreal, QC, Canada, 3 John Hopkins
University School of Medicine, Baltimore, MD, 4 Klinikum Eilbek,
Hamburg, Germany, 5 UZ Gasthuisburg, Leuven, Belgium.
1838. TNF-alpha Antagonist Therapy Leads to an Expansion of IL-17
Expressing CD4+ T Cells Both In Vitro and In Vivo. Hayley
G. Evans 2 , Nicola J. Gullick 3 , Bruce W. Kirkham 1 and Leonie
S. Taams 3 , 1 Guy’s &St Thomas’ NHS Foundation Trust, 2 Kings
College London, London, United Kingdom, 3 Kings College
London.
1839. Tocilizumab Monotherapy Improves Arterial Stiffness
Compared with Other Biologics Monotherapy in Rheumatoid
Arthritis. Kensuke Kume 1 , Kanzo Amano 1 , Susumu Yamada 1 and
Hiroyuki Ohta 2 , 1 Hiroshima Clinic, Hiroshima, Japan, 2 IGL School,
Hiroshima, Japan.
1840. Tocilizumab Treatment in Patients with Rheumatoid Arthritis
and an Inadequate Response to DMARDs and/or TNF
Inhibitors: ACT-SURE Preliminary Results. Vivian P. Bykerk 7 ,
Jose Álvaro-Gracia 3 , Jose Andres Roman Ivorra 4 , Michael T.
Nurmohamed 6 , Karel Pavelka 5 , Corrado Bernasconi 8 , Andrea
Stancati 8 , Jean Sibilia 2 and Andrew Östör and the ACT-SURE
Study Group 1 , 1 Addenbrookes Hospital, Cambridge, United
Kingdom, 2 Hautepierre Service de Rhumatologie, Strasbourg,
France, 3 Hospital Universitario de La Princesa, IIS Princesa,
Madrid, Spain, 4 Hospital Universitario Dr. Peset, Valencia, Spain,
5
Institute of Rheumatology, Prague, Czech Republic, 6 Jan van
Breemen Institute, Amsterdam, The Netherlands, 7 Mount Sinai
Hospital, Toronto, ON, Canada, 8 Roche, Basel, Switzerland.
2010 Program Book
1841. Treatment with TNF-Inhibitors Reduces Radiographic Joint
Destruction in Rheumatoid Arthritis Patients Treated in Clinical
Practice. Lykke M. Ørnbjerg 1 , Mikkel Østergaard 1 , Pernille
Bøyesen 12 , Anja Thormann 1 , Ulrik Tarp 6 , Wolfgang Böhme 13 ,
Ditte Dencker 13 , Hanne Lindegaard 15 , Uta Poulsen 14 , Anette
Hansen 2 , Vibeke Ringsdal 5 , Anette Schlemmer 5 , Niels Graudal 10 ,
Anne R. Andersen 16 , Jakob Espesen 4 , Gina Kollerup 7 , Torben G.
Christensen 11 , Randi Pelck 3 , Bente Glintborg 3 , Ole R. Madsen 2 ,
Dorte V. Jensen 8 , Ole Majgaard 9 and Merete L. Hetland 1 ,
1
DANBIO Registry and Depts. of Rheumatology, Copenhagen
University Hospitals at Hvidovre and Glostrup, Denmark,
2
Dept. of Internal Medicine and Rheumatology, Gentofte
University Hospital, Denmark, 3 Dept. of Internal Medicine,
Copenhagen University Hospital at Holbæk, Denmark, 4 Dept.
of Internal Medicine, Hospital Lillebaelt at Vejle, Denmark,
5
Dept. of Rheumatology, århus University Hospital at ålborg,
Denmark, 6 Dept. of Rheumatology, århus University Hospital,
Denmark, 7 Dept. of Rheumatology, Copenhagen University
Hospital at Frederiksberg, Denmark, 8 Dept. of Rheumatology,
Copenhagen University Hospital at Hørsholm, Denmark, 9 Dept.
of Rheumatology, Copenhagen University Hospital at Næstved,
Denmark, 10 Dept. of Rheumatology, Copenhagen University
Hospital at Rigshospitalet, Denmark, 11 Dept. of Rheumatology,
Copenhagen University Hospital at Slagelse, Denmark, 12 Dept. of
Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 13 Dept.
of Rheumatology, Hospital of South West Jutland at Esbjerg,
Denmark, 14 Dept. of Rheumatology, King Christian Xth Hospital,
Gråsten, Denmark, 15 Dept. of Rheumatology, Odense University
Hospital, Denmark, 16 Depts. of Rheumatology, Copenhagen
University Hospitals at Hvidovre and Glostrup, Denmark.
Systemic Lupus Erythematosus - Clinical Aspects and Treatment-
Epidemiology and Health Services III
1842. Accumulation of Traditional Risk Factors for Coronary Heart
Disease in Patients with Systemic Lupus Erythematosus. Rosa
W. Telles 2 , Cristina C. D. Lanna 2 , Fabricia F. Simil 1 , Luana G.
Machado 1 , Fabiana L. Sousa 1 , Luciana A. Rodrigues 2 and Antonio
L. Ribeiro 3 , 1 Hospital das Clinicas, 2 School of Medicine, 3 School
of Medicine-Universidade Federal de Minas Gerias-Brazil.
1843. Analysis of the Level of Agreement between Different
Measures of Disease Flare in an Exploratory Study of
Abatacept in Systemic Lupus Erythematosus (SLE). Caroline
Gordon 3 , Jean-Claude Becker 1 , Sheila Kelly 1 , Yun Peng 2 ,
Michael Kinaszczuk 1 and Joan T. Merrill 4 , 1 Bristol-Myers Squibb,
Princeton, NJ, 2 Bristol-Myers Squibb, Pennington, NJ, 3 University
of Birmingham, Birmingham, United Kingdom, 4 University of
Oklahoma, Oklahoma City, OK.
1844. Anti-NR2A Antibody as a Predictor for Neuropsychiatric
Systemic Lupus Erythematosus. Masanori Hanaoka 3 ,
Takahisa Gono 3 , Yasushi Kawaguchi 1 , Hirotaka Kaneko 2 , Katsuji
Nishimura 2 , Yasuhiro Katsumata 2 , Yuko Okamoto 2 , Sayumi
Baba 2 , Sayuri Kataoka 2 and Hisashi Yamanaka 4 , 1 Tokyo Women’s
Medical Univ, Tokyo, Japan, 2 Tokyo Women’s Medical Univ,
3
Tokyo Women’s Medical University, 4 Tokyo Womens Med Univ,
Shinjuku-ku, Tokyo, Japan.
1845. Assessing the ANA Test as a Screening Tool: Utility or Futility?
Aryeh M. Abeles and Micha Abeles, University of Connecticut
Health Center.
1846. Atherosclerosis in SLE: A Cross Sectional Study of 223 Patients
with 223 Individually Matched Population Controls. Johanna
T. Gustafsson 2 , Kerstin Urstad Jensen 1 , Marie Herlitz-Lindberg 1 ,
Sonia Möller 4 , Susanne Petterson 3 , Iva Gunnarsson 2 and
Elisabet Svenungsson 2 , 1 Department of Clinical Physiology,
Södersjukhuset, Karolinska Institute, Stockholm, Sweden,